Search

Your search keyword '"Duvic M."' showing total 1,023 results
Start Over Author "Duvic M."
1,023 results on '"Duvic M."'

101. Non-Hodgkin's lymphomas

Author

Zelenetz, A. D., Advani, R. H., Byrd, J. C., Czuczman, M. S., Damon, L. E., Duvic, M., Fayad, L., Forero, A., Glenn, M. J., Gockerman, J. P., Leo Gordon, Harris, N. L., Hoppe, R. T., Horwitz, S. M., Kaminski, M. S., Kim, Y. H., Lacasce, A. S., Nademanee, A., Olsen, E. A., Porcu, P., Press, O., Prosnitz, L., Smith, M. R., Sotomayor, E. M., Vose, J. M., Yahalom, J., and Yunus, F.

Subjects
Oncology, medicine.medical_specialty, Hodgkin s, business.industry, Lymphoma, Non-Hodgkin, Antineoplastic Agents, Prognosis, Internal medicine, Antineoplastic Combined Chemotherapy Protocols, medicine, Humans, Immunotherapy, Neoplasm Recurrence, Local, business, Neoplasm Staging, Stem Cell Transplantation
Published
2008

103. Final results of a multicenter phase II study of the purine nucleoside phosphorylase (PNP) inhibitor forodesine in patients with advanced cutaneous T-cell lymphomas (CTCL) (Mycosis fungoides and Sézary syndrome)

Author

Dummer, R, Duvic, M, Scarisbrick, J, Olsen, E A, Rozati, S, Eggmann, N, Goldinger, S M, Hutchinson, K, Geskin, L, Illidge, T M, Giuliano, E, Elder, J, Kim, Y H, Dummer, R, Duvic, M, Scarisbrick, J, Olsen, E A, Rozati, S, Eggmann, N, Goldinger, S M, Hutchinson, K, Geskin, L, Illidge, T M, Giuliano, E, Elder, J, and Kim, Y H

Abstract

BACKGROUND Forodesine is a potent inhibitor of purine nucleoside phosphorylase (PNP) that leads to intracellular accumulation of deoxyguanosine triphosphate (dGTP) in T and B cells, resulting in apoptosis. Forodesine has demonstrated impressive antitumor activity in early phase clinical trials in cutaneous T-cell lymphoma (CTCL). PATIENTS AND METHODS In this phase II study, patients with CTCL who had already failed three or more systemic therapies were recruited. We investigated the response rate, safety and tolerability of oral forodesine treatment in subjects with cutaneous manifestations of CTCL, stages IB, IIA, IIB, III and IVA. The safety population encompassing all stages was used for analysis of accountability, demographics and safety. The efficacy population differed from the safety population by exclusion of stage IB and IIA patients. RESULTS All 144 patients had performance status 0-2. The median duration of CTCL from diagnosis was 53 months (5-516 months). The median number of pretreatments was 4 (range: 3-15). No complete remissions were observed. In the efficacy group of patients, 11% achieved partial remission and 50% had stable disease. The median time to response was 56 days and the median duration of response was 191 days. A total of 96% of all treated patients reported one or more adverse events (AEs) and 33% reported a serious AE. The majority of AEs were classified as mild or moderate in severity. The most commonly reported AEs (>10%) were peripheral edema, fatigue, insomnia, pruritus, diarrhea, headache and nausea. Overall eight patients died during the study: five due to sepsis and infections, one due to a second malignancy (esophageal cancer), one due to disease progression and one due to liver failure. CONCLUSION Oral forodesine at a dose of 200 mg daily is feasible and shows partial efficacy in this highly selected CTCL population and some durable responses.

Published
2014

105. EORTC, ISCL, and USCLC consensus recommendations for the treatment of primary cutaneous CD30-positive lymphoproliferative disorders: lymphomatoid papulosis and primary cutaneous anaplastic large-cell lymphoma

Author

Kempf, W, Pfaltz, K, Vermeer, M, Cozzio, A, Ortiz Romero, P, Bagot, M, Olsen, E, Kim, Y, Dummer, R, Pimpinelli, N, Whittaker, S, Hodak, E, Cerroni, L, Berti, E, Horwitz, S, Prince, H, Guitart, J, Estrach, T, Sanches, J, Duvic, M, Ranki, A, Dreno, B, Ostheeren Michaelis, S, Knobler, R, Wood, G, Willemze, R, Vermeer, MH, Ortiz Romero, PL, Kim, YH, BERTI, EMILIO, Prince, HM, Sanches, JA, Willemze, R., Kempf, W, Pfaltz, K, Vermeer, M, Cozzio, A, Ortiz Romero, P, Bagot, M, Olsen, E, Kim, Y, Dummer, R, Pimpinelli, N, Whittaker, S, Hodak, E, Cerroni, L, Berti, E, Horwitz, S, Prince, H, Guitart, J, Estrach, T, Sanches, J, Duvic, M, Ranki, A, Dreno, B, Ostheeren Michaelis, S, Knobler, R, Wood, G, Willemze, R, Vermeer, MH, Ortiz Romero, PL, Kim, YH, BERTI, EMILIO, Prince, HM, Sanches, JA, and Willemze, R.

Abstract

Primary cutaneous CD30(+) lymphoproliferative disorders (CD30(+) LPDs) are the second most common form of cutaneous T-cell lymphomas and include lymphomatoid papulosis and primary cutaneous anaplastic large-cell lymphoma. Despite the anaplastic cytomorphology of tumor cells that suggest an aggressive course, CD30(+) LPDs are characterized by an excellent prognosis. Although a broad spectrum of therapeutic strategies has been reported, these have been limited mostly to small retrospective cohort series or case reports, and only very few prospective controlled or multicenter studies have been performed, which results in a low level of evidence for most therapies. The response rates to treatment, recurrence rates, and outcome have not been analyzed in a systematic review. Moreover, international guidelines for staging and treatment of CD30(+) LPDs have not yet been presented. Based on a literature analysis and discussions, recommendations were elaborated by a multidisciplinary expert panel of the Cutaneous Lymphoma Task Force of the European Organization for Research and Treatment of Cancer, the International Society for Cutaneous Lymphomas, and the United States Cutaneous Lymphoma Consortium. The recommendations represent the state-of-the-art management of CD30(+) LPDs and include definitions for clinical endpoints as well as response criteria for future clinical trials in CD30(+) LPDs.

Published
2011

107. A Phase Ii International, Multicenter Study of Oral Panobinostat (lbh589) in Patients With Refractory Cutaneous T-cell Lymphoma (ctcl)

Author

UCL - Autre, Bernengo, M. G., Vanaclocha, F., Duvic, M., Kuzel, T., Kerdel, F., Pinter-Brown, L., Bosly, André, Okada, C., Breneman, D., Zinzani, P. L., Becker, J., Hughey, L., Ardaiz, M., Zain, J., Zhang, L., Hirawat, S., Laird, G., Johnson, David, Prince, H. M., 13th Congress of the European-Hematology-Association, UCL - Autre, Bernengo, M. G., Vanaclocha, F., Duvic, M., Kuzel, T., Kerdel, F., Pinter-Brown, L., Bosly, André, Okada, C., Breneman, D., Zinzani, P. L., Becker, J., Hughey, L., Ardaiz, M., Zain, J., Zhang, L., Hirawat, S., Laird, G., Johnson, David, Prince, H. M., and 13th Congress of the European-Hematology-Association

Published
2008

108. European Organization for Research and Treatment of Cancer and International Society for cutaneous lymphoma Consensus recommendations for the management of cutaneous B-cell lymphomas

Author

Senff, N, Noordijk, E, Kim, Y, Bagot, M, Berti, E, Cerroni, L, Dummer, R, Duvic, M, Hoppe, R, Pimpinelli, N, Rosen, S, Vermeer, M, Whittaker, S, Willemze, R, Senff, NJ, Noordijk, EM, Kim, YH, Hoppe, RT, Rosen, ST, Vermeer, MH, Willemze, R., BERTI, EMILIO, Senff, N, Noordijk, E, Kim, Y, Bagot, M, Berti, E, Cerroni, L, Dummer, R, Duvic, M, Hoppe, R, Pimpinelli, N, Rosen, S, Vermeer, M, Whittaker, S, Willemze, R, Senff, NJ, Noordijk, EM, Kim, YH, Hoppe, RT, Rosen, ST, Vermeer, MH, Willemze, R., and BERTI, EMILIO

Abstract

Primary cutaneous B-cell lymphomas (CBCL) represent approximately 20% to 25% of all primary cutaneous lymphomas. With the advent of the World Health Organization-European Organization for Research and Treatment of Cancer (EORTC) Consensus Classification for Cutaneous Lymphomas in 2005, uniform terminology and classification for this rare group of neoplasms were introduced. However, staging procedures and treatment strategies still vary between different cutaneous lymphoma centers, which may be because consensus recommendations for the management of CBCL have never been published. Based on an extensive literature search and discussions within the EORTC Cutaneous Lymphoma Group and the International Society for Cutaneous Lymphomas, the present report aims to provide uniform recommendations for the management of the 3 main groups of CBCL. Because no systematic reviews or (randomized) controlled trials were available, these recommendations are mainly based on retrospective studies and small cohort studies. Despite these limitations, there was consensus among the members of the multidisciplinary expert panel that these recommendations reflect the state-of-the-art management as currently practiced in major cutaneous lymphoma centers. They may therefore contribute to uniform staging and treatment and form the basis for future clinical trials in patients with a CBCL.

Published
2008

109. Sorafenib Suppresses JNK-Dependent Apoptosis through Inhibition of ZAK

Author

Vin, H., primary, Ching, G., additional, Ojeda, S. S., additional, Adelmann, C. H., additional, Chitsazzadeh, V., additional, Dwyer, D. W., additional, Ma, H., additional, Ehrenreiter, K., additional, Baccarini, M., additional, Ruggieri, R., additional, Curry, J. L., additional, Ciurea, A. M., additional, Duvic, M., additional, Busaidy, N. L., additional, Tannir, N. M., additional, and Tsai, K. Y., additional

Published
2013
Full Text
View/download PDF

111. Interferon-inducible protein 10 as a possible factor in the pathogenesis of cutaneous T-cell lymphomas

Author

Ah, Sarris, Daliani D, Ulmer R, Crow M, He, Broxmeyer, Michael Reiss, Karasavvas N, Ad, Zelenetz, Pugh W, Cabanillas F, Ab, Deisseroth, and Duvic M

Subjects
Adult, Aged, 80 and over, Keratinocytes, Male, Skin Neoplasms, Middle Aged, Lymphoma, T-Cell, Cutaneous, Chemokine CXCL10, Interferon-gamma, Cytokines, Humans, Female, Chemokines, CXC, Cell Division, Aged
Abstract

Human IFN-gamma-inducible protein 10 (IP-10), a C-X-C chemokine secreted by IFN-gamma-stimulated keratinocytes, is chemotactic for normal CD4-positive lymphocytes and inhibits the proliferation of early subsets of normal and of leukemic hemopoietic progenitors. Cutaneous T-cell lymphoma (CTCL) is an indolent lymphoproliferative disorder of CD4-positive lymphocytes that remain confined to the skin for many years before visceral dissemination. Because IFN-gamma mRNA was detected in the epidermis of CTCL lesions, we decided to investigate the role of IP-10 in the epidermotropism of CTCL by determining its expression in normal skin and in CTCL lesions. Using purified recombinant IP-10 (rIP-10) or a recombinant fusion protein between IP-10 and the straight phi10 protein of phage T7, we generated rabbit antisera that recognized and neutralized rIP-10. Immunoperoxidase staining of normal epidermis demonstrated that IP-10 was expressed by basal keratinocytes but not by the more differentiated cells. In the often hyperplastic epidermis overlying CTCL lesions, IP-10 immunostaining was enhanced compared to normal skin and extended to the suprabasal keratinocytes in 28 of 29 patients for a frequency of 97% and a 95% confidence interval of 82-100%. However, IP-10 was detectable in the dermal or epidermal lymphoid infiltrates in only 3 of 29 patients (10%; 95% confidence interval, 2-29%). Skin clinically free of CTCL demonstrated normal IP-10 immunostaining. In one patient who had matching biopsies performed before and after treatment, IP-10 was overexpressed before treatment but was normally expressed at remission. The in vitro proliferation of primary normal human keratinocytes was inhibited in a dose-dependent manner by rIP-10. These results suggest that IP-10 plays a role in the epidermotropism of CTCL. Additional work is needed to determine whether IP-10 stimulates or inhibits CTCL proliferation. A better understanding of the growth controls operating in CTCL may be useful in the development of curative strategies for this disorder.

Published
1997

116. Presence of frequent underlying RAS mutations in cutaneous squamous cell carcinomas and keratoacanthomas (cuSCC/KA) that develop in patients during vemurafenib therapy.

Author

Lacouture, M. E., primary, Chapman, P. B., additional, Ribas, A., additional, Sosman, J. A., additional, McArthur, G. A., additional, Flaherty, K. T., additional, Kim, K. B., additional, Puzanov, I., additional, Nolop, K. B., additional, Joe, A. K., additional, Spleiss, O., additional, Koehler, A., additional, Wu, W., additional, Robert, C., additional, Hauschild, A., additional, Schadendorf, D., additional, Troy, J. L., additional, Duvic, M., additional, and Trunzer, K., additional

Published
2011
Full Text
View/download PDF

128. Belinostat (PXD101) in Patients with Recurrent or Refractory Peripheral or Cutaneous T-Cell Lymphoma: Results of a Phase II Study.

Author

Advani, Ranjana, primary, Hymes, K., additional, Pohlman, B., additional, Jacobsen, E., additional, McDonnell, J., additional, Belt, R., additional, Lerner, A., additional, Kim, Y., additional, Mundis, R., additional, Mansfield, T., additional, Buhl-Jensen, P., additional, Ooi, C.E., additional, Duvic, M., additional, and Foss, F., additional

Published
2007
Full Text
View/download PDF

146. Long-range amplification of genomic DNA detects the t(2;5)(p23;q35) in anaplastic large-cell lymphoma, but not in other non-Hodgkin's lymphomas, Hodgkin's disease, or lymphomatoid papulosis

Author

Sarris, A.H., primary, Luthra, R., additional, Papadimitracopoulou, V., additional, Waasdorp, M., additional, Dimopoulos, M.A., additional, McBride, J.A., additional, Cabanillas, F., additional, Duvic, M., additional, Deisseroth, A., additional, Morris, S.W., additional, and Pugh, W.C., additional

Published
1997
Full Text
View/download PDF

147. Amplification of genomic DNA demonstrates the presence of the t(2;5) (p23;q35) in anaplastic large cell lymphoma, but not in other non- Hodgkin's lymphomas, Hodgkin's disease, or lymphomatoid papulosis

Author

Sarris, AH, primary, Luthra, R, additional, Papadimitracopoulou, V, additional, Waasdorp, M, additional, Dimopoulos, MA, additional, McBride, JA, additional, Cabanillas, F, additional, Duvic, M, additional, Deisseroth, A, additional, Morris, SW, additional, and Pugh, WC, additional

Published
1996
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results